Christine Regan Lindenboom | Alnylam Pharmaceuticals, Inc. |
John M. Maraganore | Alnylam Pharmaceuticals, Inc. |
Yvonne L. Greenstreet | Alnylam Pharmaceuticals, Inc. |
Manmeet Singh Soni | Alnylam Pharmaceuticals, Inc. |
Barry E. Greene | Alnylam Pharmaceuticals, Inc. |
Gena Wang | Barclays Capital, Inc. |
Terence Flynn | Goldman Sachs & Co. LLC |
Ritu Baral | Cowen & Co. LLC |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Madhu Kumar | B. Riley FBR, Inc. |
Anupam Rama | JPMorgan Securities LLC |
Alan Carr | Needham & Co. LLC |
Maury Raycroft | Jefferies LLC |
Konstantinos Aprilakis | JMP Securities LLC |
Christopher N. Marai | Nomura/Instinet |
Good day, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Q2 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time.
As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ms.